이종이식 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Xenotransplantation Market was valued at USD 47.9 billion in 2024 and is estimated to grow at a CAGR of 8.8% to reach USD 109.7 billion by 2034. The growing mismatch between organ demand and availability has sparked renewed interest in xenotransplantation as a long-term solution to the organ shortage crisis. As technological progress accelerates in genetic modification, particularly through tools like CRISPR/Cas9, scientists are now working with genetically engineered animal organs that demonstrate reduced immune rejection risks. Strong financial backing from biotech firms, venture capital groups, and government agencies is further pushing the boundaries of xenotransplantation innovation and bringing it closer to mainstream clinical adoption.

Rapid breakthroughs in fields such as genetic engineering, advanced biotechnology, and artificial intelligence are reshaping xenotransplantation's future potential. Predictive AI tools are playing a larger role in organ matching and immune compatibility tracking, enhancing transplant success rates and minimizing rejection events. Such advancements mark a turning point where xenotransplantation may soon transition from experimental to routine medical practice. The outlook includes the growing integration of smart systems, bioengineered tissues, and improved immunosuppressive protocols, which could significantly increase the reliability and accessibility of cross-species organ transplantation.

In 2024, the Xeno products segment generated a 75.2% share and continues to dominate due to its role in easing transplant wait times. These products, derived from genetically altered animal sources, offer a practical solution for patients awaiting organ transplants. Improvements in engineered tissues and immunomodulatory strategies have helped reduce complications related to immune rejection and aggressive immunosuppressive therapy. The evolution of supportive biomaterials and compatible tissues is expected to enhance the clinical success rate and expand adoption across global healthcare systems.

The kidney transplant segment led the market in 2024 with a 47.7% share. Xenotransplantation efforts are particularly focused on kidney replacement solutions due to the high prevalence of end-stage renal disease (ESRD) and the scarcity of human donor kidneys. With an estimated 850 million individuals living with kidney disease globally-especially in lower-income countries with inadequate access to care-the urgency for alternative solutions like xenotransplantation is intensifying. Genetically engineered pig kidneys offer a scalable and potentially life-saving intervention for this expanding patient population.

United States Xenotransplantation Market was valued at USD 13.8 billion in 2024 and is estimated to reach USD 32.7 billion by 2034. The continued gap between donor organ supply and patient needs has placed xenotransplantation at the forefront of medical innovation in the country. National funding and grant support have enabled key institutions to push development forward in organ preservation, genetic modifications, and transplant trials. The country is emerging as a global leader in this field, with several organizations contributing to clinical advancements and scientific breakthroughs that are driving this transformative market.

Key players shaping the landscape of the Global Xenotransplantation Industry include XVIVO, Pfizer, Makana Therapeutics, eGenesis, OrganOX, Sanofi, Astellas Pharma, Novartis, Bristol-Myers Squibb Company, United Therapeutics, F. Hoffmann-La Roche, Nzeno, and Preservation Solutions. Leading companies in the xenotransplantation market are focusing on advancing genetic modification techniques to enhance compatibility and reduce immune rejection risks. Many are expanding partnerships with research institutes and clinical trial networks to accelerate innovation and validate outcomes. Several players are investing in AI-driven platforms for immune profiling and organ matching, increasing transplant success rates. Funding is being strategically directed toward preclinical studies and bioengineering initiatives to improve organ viability and patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
  • 2.1.1 By product type trends
  • 2.1.2 By immunosuppression drug type
  • 2.1.3 By application
  • 2.1.4 By end use
  • 2.1.5 By region

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for tissue and organ transplantation
    • 3.2.1.2 Advancements in genetic engineering
    • 3.2.1.3 Growing number of surgical procedures
    • 3.2.1.4 High investment in research and development activities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 Dearth of skilled professionals
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of Clinical Trials and Early Access Programs
    • 3.2.3.2 Development of Specialized Immunosuppressive and Anti-Rejection Therapies
• 3.3 Growth potential analysis
  • 3.3.1 By product type
  • 3.3.2 By immunosuppression drug type
  • 3.3.3 By application
  • 3.3.4 By end use
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technology landscape
• 3.6 Global xenotransplants volume analysis, 2025 – 2034
• 3.7 Pipeline analysis
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Competitive market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Current and future perspectives on immunosuppressants in xenotransplantation

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Organ preservation solution
• 5.3 Transplant diagnostics
• 5.4 Xeno products
  • 5.4.1 Organ
  • 5.4.2 Cell
  • 5.4.3 Tissue

Chapter 6 Market Estimates and Forecast, By Immunosuppression Drug Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Standard immunosuppressants
  • 6.2.1 Calcineurin inhibitors
  • 6.2.2 Anti-proliferative agents
  • 6.2.3 mTOR inhibitors
• 6.3 Xenotransplant-specific immunosuppressants
  • 6.3.1 Costimulation blockade therapy
  • 6.3.2 Complement inhibitors
  • 6.3.3 B-cell and T-cell modulators

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Kidney
• 7.3 Heart
• 7.4 Liver
• 7.5 Lung
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Transplant centers
• 8.3 Hospitals
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.4 Argentina
• 9.6 Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Astellas Pharma
• 10.2 Bristol-Myers Squibb Company
• 10.3 eGenesis
• 10.4 F. Hoffmann-La Roche
• 10.5 Makana Therapeutics
• 10.6 Novartis
• 10.7 Nzeno
• 10.8 OrganOX
• 10.9 Pfizer
• 10.10 Preservation Solutions
• 10.11 Sanofi
• 10.12 United Therapeutics
• 10.13 XVIVO